Conjunctivitis in atopic dermatitis patients treated with dupilumab—Worsening of pre‐existing disease or de novo development?
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19126 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von C M Olesen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermato-venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Conjunctivitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Dupilumab, a monoclonal antibody targeting IL-4/IL-13 signalling, was the first targeted therapy approved for treatment of moderate-to-severe atopic dermatitis (AD) by the US Food and Drug Administration and European Medical Agency.1 Dupilumab induces rapid improvement of signs and symptoms of AD in majority of patients with a mean percentage improvement of clinical severity scores of 69.6% in real-life studies.1 The main reason for dupilumab discontinuation is development of ocular side effects.2 Several ocular side effects have been reported including conjunctivitis, blepharitis, keratitis, dry eye disease and conjunctival fibrosis. According to a systematic review and meta-analysis, the most common side effect to dupilumab therapy is conjunctivitis reported in 26.1% of AD patients treated with dupilumab.1 However, irrespective of treatment with dupilumab, conjunctivitis is common in patients with AD with a life-time prevalence of 66%.3 Hence, it has been speculated whether conjunctivitis during dupilumab treatment is a result of worsening of already prevalent conjunctivitis or de novo development.2 At present, real-world studies on safety of dupilumab have been limited by retrospective design and/or lack of thorough ophthalmologic assessment of ocular surface disease prior to treatment initiation.2 The work by Costedoat et al.4 represents the first larger, prospective study that includes a systematic, standardized ophthalmologic assessment prior to and following 16 weeks of dupilumab therapy in moderate-to-severe AD patients and is therefore pivotal in differentiating between dupilumab-exacerbated and dupilumab-induced ocular surface disease with primary focus on conjunctivitis. This multicentre study included 181 adult AD patients of which 27 had conjunctivitis at treatment initiation. Dupilumab-induced conjunctivitis was defined as either worsening of pre-existing conjunctivitis or de novo development of conjunctivitis and was observed in 34 patients after 16 weeks of dupilumab therapy. Of these, 32 patients were classified as having de novo conjunctivitis while two patients experienced worsening of pre-existing conjunctivitis. Thus, the results indicated de novo development as the most common nature of dupilumab-induced conjunctivitis. However, at treatment initiation and all follow-up visits, patients were examined by an ophthalmologist; hence, it is possible that prescriptions have prevented development and exacerbation of pre-existing conjunctivitis thereby limiting the interpretation of the results. Patients with dupilumab-induced conjunctivitis were significantly more likely to develop blepharitis compared to patients without dupilumab-induced conjunctivitis, and 30 patients had concomitant blepharitis defined as blepharoconjunctivitis. Contrary to findings of previous studies, neither AD severity, current or previous conjunctivitis or presence of atopic comorbidities were associated with an increased risk of dupilumab-induced conjunctivitis,1, 2 while head-and-neck dermatitis, erythroderma and dry eye syndrome were identified as risk factors of dupilumab-induced conjunctivitis. With respect to other potential ocular side effects, neither keratitis, dry eye syndrome or conjunctival fibrosis increased in prevalence following dupilumab therapy indicating that these diseases may be linked to the natural course of AD and not dupilumab therapy. The finding that dry eye syndrome increased the risk of dupilumab-induced conjunctivitis is interesting since depletion of goblet cells and subsequent decrease in mucin production and tear instability has been proposed as a potential mechanism for this side effect.2, 5 However, the underlying pathophysiology of dupilumab-induced conjunctivitis has still not been established, and several potential mechanisms have been proposed such as increased colonization with demodex mites resulting in Th17 activation, increase in eosinophils and increase in conjunctivitis promoting ligands such as OX40L.1, 2 Interestingly, dupilumab-induced conjunctivitis seems to be caused by a unique interplay between AD disease mechanisms and dupilumab therapy since this side effect is rarely reported in patients with asthma, chronic rhinosinusitis or eosinophilic oesophagitis treated with dupilumab.1, 2 Overall, the study by Costedoat et al. provides some important new findings of dupilumab-induced conjunctivitis by showing that de novo development is the primary origin of this side effect. Although the results must be confirmed in larger studies, they emphasize that current or previous conjunctivitis should not be a contraindication for receiving dupilumab therapy while presence of head-and-neck dermatitis, erythroderma and dry eye syndrome might increase the risk of conjunctivitis if treated with dupilumab. Future studies should focus on establishing the pathophysiological mechanisms underlying dupilumab-induced conjunctivitis in order to promote a systematic approach for prevention and management of this frequent side effect in patients with AD. C.M.O.: Industrial postdoc at Leo Pharma and Bispebjerg hospital. A.S.H.: None. Data sharing not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermato-venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: C M Olesen, A S Halling
Zitieren
APA
Olesen, C. M., & Halling, A. S. (2023). Conjunctivitis in atopic dermatitis patients treated with dupilumab—Worsening of pre‐existing disease or de novo development?. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19126
Vancouver
Olesen CM, Halling AS. Conjunctivitis in atopic dermatitis patients treated with dupilumab—Worsening of pre‐existing disease or de novo development?. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19126
BibTeX
@article{Olesen2023,
author = {Olesen, C M and Halling, A S},
title = {Conjunctivitis in atopic dermatitis patients treated with dupilumab—Worsening of pre‐existing disease or de novo development?},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19126}
}
EUVIMED